Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semapimod for Moderate to Severe Crohn's Disease
NCT00038766Phase 2Terminated
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jun 2002
- Primary completion
- Jun 2003
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semapimod in Crohn's disease (3 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Change in Crohn's Disease Activity Index at Day 29. Started Jun 2002; status: terminated.
02
Drugs
semapimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00038766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038766.